BR103354 是一种口服有效的选择性成纤维细胞活化蛋白 (FAP) 抑制剂,对 hFAP 的 IC50 值为 14 nM,可恢复 hFGF21 与 FAP 共处理降低的磷酸化 ERK 和 Glut1 水平,降低非空腹血糖浓度,改善葡萄糖耐量,减少肝脏甘油三酯含量,改善肝脂肪变性和肝纤维化,并可用于 2 型糖尿病和非酒精性脂肪性肝炎的研究。
产品编号: MS-A89692 CAS No.: 2505339-87-5 分子式: C19H15F2N5O2S 分子量: 415.42
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

BR103354 是一种口服有效的选择性成纤维细胞活化蛋白 (FAP) 抑制剂,对 hFAP 的 IC50 值为 14 nM,可恢复 hFGF21 与 FAP 共处理降低的磷酸化 ERK 和 Glut1 水平,降低非空腹血糖浓度,改善葡萄糖耐量,减少肝脏甘油三酯含量,改善肝脂肪变性和肝纤维化,并可用于 2 型糖尿病和非酒精性脂肪性肝炎的研究。

生物实验数据

生物活性 BR103354 is an orally active and selective fibroblast activation protein (FAP) inhibitor with an IC50 value of 14 nM against hFAP that restores the decreased phosphorylated ERK and Glut1 levels induced by co-treatment with hFGF21 and FAP, lowers non-fasting blood glucose concentrations, improves glucose tolerance, reduces hepatic triglyceride content, ameliorates hepatic steatosis and liver fibrosis, and can be used for research on type 2 diabetes and non-alcoholic steatohepatitis.
IC50 & Target

GLUT1

 

体外研究
(In Vitro)

BR103354 (0.03 nM-100 μM; 60 min) 可强效且选择性地抑制纯化的 hFAP,其 IC50 为 14 nM。
BR103354 在小鼠、食蟹猴和人源样本中以相近效力抑制血清 FAP 活性,其 IC50 值约为 27 至 31 nM。

Western Blot Analysis

Cell Line: Differentiated 3T3/L1 adipocytes
Concentration: 5 μM
Incubation Time: 2 h (pre-incubation of hFGF21 with FAP; then added to cells)
Result: Restored phosphorylated ERK and Glut1 levels that had been reduced by co-treatment of hFGF21 with FAP, matching levels observed with hFGF21 treatment alone.
体内研究
(In Vivo)

BR103354 (20-50 mg/kg;口服) 可使 ob/ob 小鼠的非空腹血糖 AUC 降低 40%-45%,并能在长达 9 小时内抑制 FAP 活性超过 70%。
BR103354 (20-50 mg/kg;口服;每日 1 次;连续 4 周) 可降低 ob/ob 小鼠的非空腹血糖,抑制 FAP 活性达 ≥80%,使血清 FGF21 水平升高约 1.4 倍,同时改善其胰岛素抵抗、葡萄糖耐量及肝脏脂肪变性。
BR103354 (50 mg/kg;鼻内给予) 可抑制 FAP 活性达 65%-83%,并使正常食蟹猴体内完整 FGF21 水平升高 1.5-3.5 倍。
BR103354 (10-30 mg/kg;口服;每日 1 次;连续 10 周) 可抑制 FAP 活性,使血清 FGF21 水平升高 1.5-1.9 倍,降低肝酶及代谢生物标志物水平,并改善 CDAHFD 诱导的 NASH 小鼠的肝脂肪变性与纤维化。

Animal Model: ob/ob (8-week-old male; spontaneous obese, diabetic model)
Dosage: 20 mg/kg; 50 mg/kg
Administration: p.o.; single dose
Result: Reduced average nonfasting blood glucose to 178 mg/dL (20 mg/kg group) and 154 mg/dL (50 mg/kg group) at 3 hours post-administration.
Decreased blood glucose AUC by 40-45% relative to control.
Inhibited FAP activity by more than 70% at 1 hour post-administration, with inhibition maintained up to 9 hours.
Elevated plasma intact hFGF21 levels until 3 hours post-administration, then dropped below 10 ng/mL by 6 hours.
Animal Model: ob/ob (8-week-old male; spontaneous obese, diabetic model)
Dosage: 20 mg/kg; 50 mg/kg
Administration: p.o.; once daily; 4 weeks
Result: Significantly reduced nonfasting blood glucose levels starting at week 2 (P<0.01) and further reduced at week 3 (P<0.001) relative to vehicle.
Inhibited FAP activity by at least 80% at week 4 relative to vehicle.
Increased serum total FGF21 levels by approximately 1.4-fold at week 4.
Showed significantly improved glucose tolerance (reduced OGTT AUC) in the 50 mg/kg group.
Significantly reduced fasting body weight, liver weight, fasting blood glucose, insulin levels, and HOMA-IR relative to vehicle.
Significantly reduced serum ALT, AST, and total cholesterol levels; serum TG and NEFA levels were unaltered.
Decreased liver TG content, with reduced Oil Red O stained area relative to vehicle.
Reduced mRNA expression of lipogenesis/steatosis-related genes, and increased fatty acid oxidation-related genes (MCAD, PPARα) in liver.
Elevated white adipose tissue adiponectin mRNA expression.
Increased ERK phosphorylation in white adipose tissue relative to vehicle.
Animal Model: C57BL/6J (5-week-old male; NASH induced by CDAHFD feeding for 4 weeks prior to treatment)
Dosage: 10 mg/kg; 30 mg/kg
Administration: p.o.; once daily; 10 weeks
Result: Inhibited FAP activity in a dose-dependent manner relative to vehicle.
Increased serum FGF21 levels by 1.5-1.9-fold in treatment groups.
Reduced plasma ALT, AST, total cholesterol, TG, and glucose levels relative to vehicle.
Significantly reduced steatosis scores and Picrosirius red staining (fibrosis) relative to vehicle.

化学信息

分子量 415.42
分子式 C19H15F2N5O2S
CAS No. 2505339-87-5

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础